CN112359125A - Method for rapidly detecting cryptococcus gatherensis - Google Patents
Method for rapidly detecting cryptococcus gatherensis Download PDFInfo
- Publication number
- CN112359125A CN112359125A CN202011254539.1A CN202011254539A CN112359125A CN 112359125 A CN112359125 A CN 112359125A CN 202011254539 A CN202011254539 A CN 202011254539A CN 112359125 A CN112359125 A CN 112359125A
- Authority
- CN
- China
- Prior art keywords
- cryptococcus
- probe
- 10nmol
- primer
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 title claims abstract description 33
- 241001337994 Cryptococcus <scale insect> Species 0.000 title claims abstract 7
- 238000006243 chemical reaction Methods 0.000 claims abstract description 22
- 238000012408 PCR amplification Methods 0.000 claims abstract description 7
- 201000007336 Cryptococcosis Diseases 0.000 claims description 50
- 241000221204 Cryptococcus neoformans Species 0.000 claims description 49
- 239000000523 sample Substances 0.000 claims description 38
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 6
- 239000003153 chemical reaction reagent Substances 0.000 claims description 6
- 108090000790 Enzymes Proteins 0.000 claims description 5
- 102000004190 Enzymes Human genes 0.000 claims description 5
- 239000000872 buffer Substances 0.000 claims description 5
- 238000012360 testing method Methods 0.000 claims description 5
- 229910021642 ultra pure water Inorganic materials 0.000 claims description 5
- 239000012498 ultrapure water Substances 0.000 claims description 5
- 238000011144 upstream manufacturing Methods 0.000 claims description 4
- 210000004369 blood Anatomy 0.000 claims description 3
- 239000008280 blood Substances 0.000 claims description 3
- 210000001124 body fluid Anatomy 0.000 claims description 3
- 239000010839 body fluid Substances 0.000 claims description 3
- 238000012257 pre-denaturation Methods 0.000 claims description 3
- 238000001514 detection method Methods 0.000 abstract description 14
- 230000035945 sensitivity Effects 0.000 abstract description 13
- 230000002538 fungal effect Effects 0.000 abstract description 2
- 241001527609 Cryptococcus Species 0.000 description 64
- 108020004414 DNA Proteins 0.000 description 16
- 238000003752 polymerase chain reaction Methods 0.000 description 14
- 230000003321 amplification Effects 0.000 description 12
- 238000003199 nucleic acid amplification method Methods 0.000 description 12
- 108090000623 proteins and genes Proteins 0.000 description 8
- 238000003745 diagnosis Methods 0.000 description 5
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 241000222122 Candida albicans Species 0.000 description 3
- 238000007400 DNA extraction Methods 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 3
- 241000191967 Staphylococcus aureus Species 0.000 description 3
- 241000193998 Streptococcus pneumoniae Species 0.000 description 3
- 241000223230 Trichosporon Species 0.000 description 3
- 241000222126 [Candida] glabrata Species 0.000 description 3
- 229940095731 candida albicans Drugs 0.000 description 3
- 208000032343 candida glabrata infection Diseases 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 229940031000 streptococcus pneumoniae Drugs 0.000 description 3
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 201000009906 Meningitis Diseases 0.000 description 2
- 206010035664 Pneumonia Diseases 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000003753 real-time PCR Methods 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 229940126585 therapeutic drug Drugs 0.000 description 2
- APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000272201 Columbiformes Species 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 108091023242 Internal transcribed spacer Proteins 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- 208000003217 Tetany Diseases 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 1
- 229960003942 amphotericin b Drugs 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 108091036078 conserved sequence Proteins 0.000 description 1
- -1 dNTPs Substances 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 229960004413 flucytosine Drugs 0.000 description 1
- XRECTZIEBJDKEO-UHFFFAOYSA-N flucytosine Chemical compound NC1=NC(=O)NC=C1F XRECTZIEBJDKEO-UHFFFAOYSA-N 0.000 description 1
- 238000001917 fluorescence detection Methods 0.000 description 1
- 244000053095 fungal pathogen Species 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000012165 high-throughput sequencing Methods 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 238000007899 nucleic acid hybridization Methods 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 239000011368 organic material Substances 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 125000006853 reporter group Chemical group 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000011895 specific detection Methods 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 150000003852 triazoles Chemical class 0.000 description 1
- 108700026220 vif Genes Proteins 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
- C12Q1/6895—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for plants, fungi or algae
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/686—Polymerase chain reaction [PCR]
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Botany (AREA)
- Mycology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
The invention belongs to the technical field of fungal etiology detection, and discloses a method for rapidly detecting Cryptococcus gatherens, which comprises the following steps: step 1) selecting a sample to be detected; step 2), extracting the DNA of the Cryptococcus gatherens; step 3) preparing a real-time fluorescent PCR reaction system; and 4) performing fluorescent PCR amplification. The kit can quickly and accurately detect the cryptococcus gatherensis, and has higher sensitivity and specificity.
Description
Technical Field
The invention belongs to the technical field of fungal etiology detection, and particularly relates to a method for accurately detecting Cryptococcus gatherensis.
Background
Cryptococcus is a pathogen that can cause cryptococcosis. The medium is generally dry pigeon feces, and reports are rarely transmitted from person to person. No specific medicine exists, and symptomatic treatment is generally carried out. Cryptococcosis is a pulmonary or disseminated infectious disease caused by cryptococci, mainly resulting in pneumonia and meningitis, and also in infections of the skin, bones or internal organs. Clinically, the diagnosis is carried out by combining the clinical manifestations and the microscopic examination results, and then the diagnosis is confirmed by fungus culture or tissue staining. The clinical therapeutic drugs comprise amphotericin B, triazole antifungal drugs and flucytosine。
There are 37 currently identified general groups of cryptococcus, among which cryptococcus neoformans and cryptococcus gatherens are more virulent. Previously, cryptococcosis is mostly caused by cryptococcus neoformans, and there are reports on cryptococcosis gatherer. Over the last 10 years, there have been increasing reports of cryptococcosis gatherer. Cryptococcus gatherensis was previously considered a variation of Cryptococcus neoformans (serotypes B and C) and was established as an independent species until 2002. Like cryptococcus neoformans and other fungal pathogens, cryptococcus gatherensis can be isolated from soil and rotten organic material, infects hosts through inhalation of basidiospore or cryptococcus yeast cells causing pneumonia, can spread and evolve into meningitis after a latency period of 2-11 months, and the latency period for untreated immunocompromised patients can be longer. Cryptococcus neoformans is only infected by all immunodeficient hosts, whereas cryptococcus gatherer is infected by immunodeficient hosts in tropical and subtropical regions, and has different clinical manifestations, therapeutic drugs and prognosis.
The diagnosis of cryptococcosis usually relies on direct microscopy, bacterial culture of clinical specimens or detection of cryptococcal antigens in body fluids. Cryptococcus can be found by routine staining of clinical specimens, and cryptococcus in sputum or cerebrospinal fluid can be identified by india ink staining but the sensitivity is low. The detection of cryptococcus in blood by enzyme-linked immunosorbent assay (ELISA) or latex coagulation technique is more sensitive than direct microscopic examination. ABC-ELISA method and immunoradiometric method are established in China for detecting cryptococcus neoformans antigen, and specificity and sensitivity are high. However, the species of cryptococcus neoformans and cryptococcus tetani are difficult to identify in these clinical microbiological laboratories, and culture is a reliable method for differentiating cryptococcus neoformans and cryptococcus neoformans which is currently used. The simplest method for determining the cryptococcus gatherens is to separate the cryptococcus from a canavanine-glycine-bromothymol blue culture medium for culture: cryptococcus gatherensis grows on the medium and turns the medium around the colonies blue.
The method for differentiating the cryptococcus terenes and the cryptococcus neoformans through culture has the advantages of low working efficiency, long time consumption, large consumption of manpower and material resources and great limitation. The rapid and convenient detection of nucleic acid is a development trend of detecting pathogens in recent years. The literature "multiple polymerase chain reaction identification of cryptococcus neoformans grubbs, new variants and cryptococcus gatherensis, von xiagbo, journal of china dermatology, 2012" establishes a multiple Polymerase Chain Reaction (PCR) based on ribosomal intergenic spacer region (IGS) for rapidly identifying the new variants of cryptococcus neoformans, grubbs and cryptococcus gatherens, the method needs to design primers for each bacterium, the method is complicated, and the reaction is not fast enough; the patent CN2017101725670 discloses a target gene, a primer, a probe and a kit for detecting and identifying cryptococcus, belonging to the field of medical mycology. According to the target gene of cryptococcus, the primer sequence for detecting cryptococcus gene is designed to be shown in SEQ ID No.3 and SEQ ID No.4 and/or SEQ ID No.6 and SEQ ID No.7, wherein SEQ ID No.3 and SEQ ID No.4 correspond to cryptococcus neoformans, SEQ ID No.6 and SEQ ID No.7 correspond to cryptococcus gatherens, and the method can be used for specifically detecting two cryptococcus neoformans and cryptococcus gatherens in the same system.
Therefore, new techniques and methods are needed to properly detect and identify Cryptococcus gatherensis.
Disclosure of Invention
The invention provides a method for accurately detecting the cryptococcus gatherensis, aiming at overcoming the defects of complicated operation, low sensitivity, high error rate and the like of the traditional detection of the cryptococcus gatherensis, and the method can be used for diagnosis or non-diagnosis.
In order to achieve the above object, the present invention adopts the following technical solutions.
A method for rapidly detecting Cryptococcus gatherens comprises the following steps
Step 1) selecting a sample to be detected;
step 2), extracting the DNA of the Cryptococcus gatherens;
step 3) preparing a real-time fluorescent PCR reaction system;
and 4) performing fluorescent PCR amplification.
Further, the sample to be tested includes blood and body fluid.
Further, the conditions of the fluorescent PCR amplification in the step 4) are as follows: pre-denaturation at 95 ℃ for 10 min; 95 ℃ for 10s, 60 ℃ for 60s, 45 cycles.
Further, the real-time fluorescent PCR reaction system comprises a primer and a probe.
Further, the primer consists of SEQ ID NO: 1 and the sequence shown in SEQ ID NO: 2 is shown in the specification; the probe is HEX 5'-TCGGATGATGATCCTGAGACCGACG-3' BHQ 1.
Preferably, the fluorescent PCR reaction system is:
Reagents | Volume (ul) |
10×ExTag Buffer | 2.5ul |
Original DNA | 1ul |
dNTP | 2ul |
probe (10nmol/ml) | 0.5ul |
Upstream primer (10nmol/ml) | 0.5ul |
Downstream primer (10nmol/ml) | 0.5ul |
TaKara ExTag enzyme (5U/ul) | 0.25ul |
Ultrapure water | 17.25ul |
The invention also claims the application of the real-time fluorescent PCR reaction system in the simultaneous detection of cryptococcus neoformans and cryptococcus gatherens, which comprises a primer, a probe 1 and a probe 2; the primer consists of SEQ ID NO: 1 and the sequence shown in SEQ ID NO: 2 is shown in the specification; the probe 1 is as follows: FAM 5'-TCGGATGATGATCCTCAGACCGACC-3' BHQ1, wherein the probe 2 is: HEX 5'-TCGGATGATGATCCTGAGACCGACG-3' BHQ 1.
Preferably, the real-time fluorescent PCR reaction system is:
Reagents | Volume (ul) |
10×ExTag Buffer | 2.5ul |
Original DNA | 1ul |
dNTP | 2ul |
probe 1(10nmol/ml) | 0.5ul |
Probe 2(10nmol/ml) | 0.5ul |
Upstream primer (10nmol/ml) | 0.5ul |
Downstream primer (10nmol/ml) | 0.5ul |
TaKara ExTag enzyme (5U/ul) | 0.25ul |
Ultrapure water | 17.25ul |
Compared with the prior art, the invention mainly has the following advantages that:
the kit can quickly and accurately detect the cryptococcus gatherensis, and has higher sensitivity and specificity; comparing the difference of the genome sequences of dozens of cryptococcus neoformans and cryptococcus gatherens by a genomics method, selecting a conserved sequence and a difference sequence, designing a primer and a probe, and having the characteristics of high sensitivity and strong specificity in the process of detecting and identifying the cryptococcus neoformans and the cryptococcus gatherens. In addition, the kit has the characteristics of simple operation, short detection time and strong applicability when the kit is used for detecting cryptococcus neoformans and cryptococcus gatherensis, the raw materials required for detecting the cryptococcus neoformans and the cryptococcus gatherens are placed in the same reaction system, the cryptococcus neoformans and the cryptococcus gatherens can be simultaneously detected and identified, the types of pathogenic bacteria are determined, the rapid and accurate clinical diagnosis is facilitated, and valuable time is won for disease treatment.
Drawings
FIG. 1: amplification curves of cryptococcus neoformans at different concentrations of DNA (50ng, 5ng, 0.5ng, 0.05 ng);
FIG. 2: amplification curves of Cryptococcus gatherens at different concentrations of DNA (50ng, 5ng, 0.5ng, 0.05 ng);
FIG. 3: specific amplification curves of the neocryptococcus repeat three reactions;
FIG. 4: a specific amplification curve of three repeated reactions of Cryptococcus gatherensis;
FIG. 5: detecting Escherichia coli, Staphylococcus aureus, Streptococcus pneumoniae, Candida albicans, Candida glabrata, Saccharomyces cerevisiae, and Trichosporon assamici by parallel test according to a specific amplification curve of cryptococcus neoformans;
FIG. 6: the specific amplification curve of the Cryptococcus gatherensis, and a parallel test are used for detecting Escherichia coli, staphylococcus aureus, streptococcus pneumoniae, Candida albicans, Candida glabrata, Saccharomyces cerevisiae and Trichosporon assamici.
Detailed Description
Those skilled in the art can modify the process parameters appropriately to achieve the desired results with reference to the disclosure herein. It is expressly intended that all such similar substitutes and modifications which would be obvious to one skilled in the art are deemed to be included in the invention. While the products and methods of this invention have been described in terms of preferred embodiments, it will be apparent to those of skill in the art that variations and modifications, or appropriate alterations and combinations, of the products and methods described herein may be made and utilized without departing from the spirit, scope, and spirit of the invention. For a further understanding of the present invention, reference will now be made in detail to the following examples.
Example 1
Target gene, primer, probe and kit for detecting and identifying cryptococcus neoformans and cryptococcus gatherer
Dozens of genome sequences of cryptococcus neoformans and cryptococcus gatherensis are obtained by a high-throughput sequencing technology, a CAP59 sequence is selected as a target gene by comparing the difference of the genomic sequences of the cryptococcus gatherens with the dozens of cryptococcus logens through a genomics method, the gene segment is relatively conserved in two cryptococcus species, and the difference exists between the cryptococcus neoformans and the cryptococcus gatherens. The nucleotide sequence for detecting the target genes of cryptococcus neoformans and cryptococcus gatherens is shown as SEQ ID NO: 5 and SEQ ID NO: and 6.
And designing a primer by using primer software according to the sequence information of the selected target gene. Through repeated contrast analysis, a real-time fluorescent PCR detection primer and a probe which can be used for detecting and identifying cryptococcus neoformans and cryptococcus gatherens are finally designed; the specific oligonucleotide primer sequence for specifically detecting and identifying cryptococcus neoformans and cryptococcus gatherens is shown as SEQ ID NO: 1 and SEQ ID NO: 2, the primer pair is a universal primer for detecting cryptococcus neoformans and cryptococcus gatherens. The sequence of the probe for detecting cryptococcus neoformans is shown as SEQ ID NO: 3, the sequence of the probe for detecting the cryptococcus gatherer is shown as SEQ ID NO: 4, the 3 'end of the probe is connected with a fluorescence quenching group, and the 5' end of the probe is connected with a fluorescence reporter group.
The primer sequence is shown as SEQ ID NO: 1, and the following components: 5'-GTATTCGATACGGTGGTTGAACAGA-3' (Tm =62.4 ℃) and SEQ ID NO: 2, as shown in the figure: 5'-GGTTCCAACGACCAGACAAAGG-3' (Tm =63.2 ℃); the probe sequences are respectively SEQ ID NO: 3, showing: FAM 5'-TCGGATGATGATCCTCAGACCGACC-3' BHQ1 was used to detect cryptococcus neoformans (Tm =70.2 ℃), and SEQ ID NO: 4, and (2) is as follows: HEX 5'-TCGGATGATGATCCTGAGACCGACG-3' BHQ1 was used to detect cryptococcus gatherensis (Tm =71.1 ℃).
The primer specifically recognizes the sequence shown by SEQ ID NO: 5 and the sequence shown in SEQ ID NO: 6. The kit for detecting cryptococcus can be used for simultaneously detecting cryptococcus neoformans and cryptococcus gatherensis, comprises a pair of universal primers, probes for detecting the cryptococcus neoformans and the cryptococcus gatherens respectively, and also comprises buffer solution, dNTPs, MgCl2, Taq DNA polymerase and the like.
Firstly, test materials: the experimental materials are shown in Table 1
Second, main reagent and instrument
The DNA extraction adopts a yeast gene extraction kit of Tiangen company; the synthesis of primers and probes was performed by bioengineering, Inc.; DNA polymerase and dNTPs were purchased from Takara; fluorescent quantitative PCR instruments were purchased from Roche.
Third, Experimental methods
DNA extraction and concentration determination: DNA was extracted according to the DNA extraction kit instructions, and the OD260/OD280 ratio was determined by measuring the DNA content in the sample using a spectrophotometer.
The real-time fluorescent PCR reaction system is shown in Table 1. The amplification conditions were: pre-denaturation at 95 ℃ for 10 min; amplification results were obtained at 95 ℃ for 10s, 60 ℃ for 60s, and 45 cycles.
TABLE 1 real-time fluorescent PCR amplification reaction System (25ul)
Reagents | Volume (ul) |
10×ExTag Buffer | 2.5ul |
Original DNA | 1ul |
dNTP | 2ul |
FAM Probe(10nmol/ml) | 0.5ul |
HEX Probe(10nmol/ml) | 0.5ul |
Upper primer(10nmol/ml) | 0.5ul |
Lower primer(10nmol/ml) | 0.5ul |
TaKara ExTag enzyme (5U/ul) | 0.25ul |
Ultrapure water | 17.25ul |
Fourthly, analyzing and judging the amplification result
In a real-time fluorescence PCR reaction system of the sample, FAM fluorescence has fluorescence logarithm increase, and when the Ct value is less than or equal to 30.0, the detection result of cryptococcus neoformans is positive; and if the HEX fluorescence has fluorescence logarithm increase and the Ct value is less than or equal to 30.0 in the real-time fluorescence PCR reaction system of the sample, the detection result of the Cryptococcus gatherensis is positive.
Fifth, sensitivity, specificity and reproducibility assays
Sensitivity detection: the extracted template DNA of cryptococcus neoformans and cryptococcus gatherens was diluted to the following concentrations: 50 ng/ul, 5 ng/ul, 0.5 ng/ul and 0.05 ng/ul, and the lowest detectable concentration of cryptococcus neoformans and cryptococcus gatherens is obtained by detecting through a fluorescence quantitative PCR method, as shown in figure 1-2, the lowest detectable concentration of cryptococcus neoformans and cryptococcus gatherens is 0.05 ng/ul, and the sensitivity is high.
And (3) repeatability detection: the cryptococcus neoformans and cryptococcus gatherens were respectively tested repeatedly, as shown in fig. 3-4, the results of the respective three reactions were consistent, and the repeatability was excellent.
And (3) specific detection: the designed primers are used for respectively carrying out specific amplification on cryptococcus neoformans and cryptococcus gatherer, and the designed probes can identify the cryptococcus neoformans and the cryptococcus gatherer. Parallel tests were performed to detect Escherichia coli, Staphylococcus aureus, Streptococcus pneumoniae, Candida albicans, Candida glabrata, Saccharomyces cerevisiae, and Trichosporon axacuminatum, as shown in FIGS. 5-6, and the results were all negative without non-specific amplification curve.
The real-time fluorescence PCR detection method for identifying the template through specific hybridization of the primer, the probe and the template has high specificity and low false positive. The fluorescence after PCR amplification is detected, the reaction signal is amplified, and the sensitivity is greatly improved. The method skillfully utilizes the DNA high-efficiency amplification of the PCR technology, the specificity of nucleic acid hybridization and the rapidness and the sensitivity of the fluorescence detection technology, has the advantages of simple operation, time and labor saving, reliable and accurate result, high sensitivity and the like, and is used for treating cryptococcus neoformans and cryptococcus gatus
The lowest limit detectable concentration is 0.05 ng/ul, the two cryptococcus infections can be accurately distinguished, and the sensitivity is far superior to that of the existing kit. The invention is used for clinical treatment, can be beneficial to doctors to quickly distinguish and diagnose cryptococcus neoformans and cryptococcus gatherens infection diseases in early stage, improves treatment schemes and reduces abuse of drugs. The technical scheme of the invention is convenient to operate, easy to popularize and has better application prospect.
Although the present invention has been described in detail with respect to the general description and the specific embodiments, it will be apparent to those skilled in the art that modifications and improvements can be made based on the present invention. Accordingly, it is intended that all such modifications and variations as fall within the true spirit of this invention be included within the scope thereof.
Sequence listing
<110> Beijing century bed Hospital affiliated to capital medical university
<120> method for rapidly detecting Cryptococcus gatherens
<160> 6
<170> SIPOSequenceListing 1.0
<210> 1
<211> 25
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 1
gtattcgata cggtggttga acaga 25
<210> 2
<211> 22
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 2
ggttccaacg accagacaaa gg 22
<210> 3
<211> 25
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 3
tcggatgatg atcctcagac cgacc 25
<210> 4
<211> 25
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 4
tcggatgatg atcctgagac cgacg 25
<210> 5
<211> 560
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 5
acggtacgcg cctcttgtcg ggtacaagaa gccttggtcc aactctggct ggttgggcaa 60
actgtttggc ggtaagagtg attcccacct gaccatggcg tcgaccactg gaaacgacag 120
gatggacagt atcaagcggg atctgcaagc gaggcagcac aagtacttct tcgccatcaa 180
cctgtacaac tcgtttgacg ttatccctga tatctttgcg acactcttcc gagcagctgc 240
catcttgggc taccacaatg tctttgtctc catttacgaa aacggttcca acgaccagac 300
aaaggcactc ttgaagattt ttgatgccct cgcgcgaacg gtcggtctga ggatcatcat 360
ccgaacatct atgcgtaccc gcggtctgtt caaccatcgt atcgaatacc tcgccgaagt 420
tcgaaacgcc gccatgctgc ccctccacga gcttcgtgac aatgacggag aagtcttcga 480
ctcggtcgtt ttcatgaatg atatcttgcc ttgcgtggac gacttgctcg agttgatttg 540
gcagagtagg agacagaatg 560
<210> 6
<211> 557
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 6
acggtacgcg ccgctcgtag gctacaagaa accgtggtcc aactctggct ggttgcgcaa 60
gctgtttggc ggctcagacg cccagtccac catggcgtcc atcaccggga acgatcggat 120
ggacgtcatc aagagggatc tccaggcgag gcagcacaag tactttttcg ccatcaactt 180
gtacaactcg tttgacgtta tccccgatat ctttgcaacg ctcttccggg cagccgccat 240
cttgggatac cacaatgtct ttgtctccat ctacgaaaac ggttccaacg accagacaaa 300
ggcgctcttg aagattttcg atgccctcgc gcggaccgtc ggtctcagga tcatcatccg 360
aacatccatg cgtacccgtg gtctgttcaa ccaccgtatc gaataccttg ccgaagtccg 420
aaacgccgcc atgctgcccc tccacgaact ccgtgacaat gacggcgaag tctttgactc 480
ggtcgtcttc atgaacgata tcttgccctg tgtcgacgac ttgctcgagt tgatctggca 540
gagtagaaga cagaatg 557
Claims (8)
1. A method for rapidly detecting Cryptococcus gatherens, which is characterized by comprising the following steps:
step 1) selecting a sample to be detected;
step 2), extracting the DNA of the Cryptococcus gatherens;
step 3) preparing a real-time fluorescent PCR reaction system;
and 4) performing fluorescent PCR amplification.
2. The method of claim 1, wherein the test sample comprises blood and body fluids.
3. The method according to claim 1, wherein the conditions for the fluorescent PCR amplification in step 4) are as follows: pre-denaturation at 95 ℃ for 10 min; 95 ℃ for 10s, 60 ℃ for 60s, 45 cycles.
4. The method of claim 1, wherein the real-time fluorescent PCR reaction system comprises primers and probes.
5. The method of claim 4, wherein the primer consists of SEQ ID NO: 1 and the sequence shown in SEQ ID NO: 2 is shown in the specification; the probe is HEX 5'-TCGGATGATGATCCTGAGACCGACG-3' BHQ 1.
6. The method of claim 5, wherein the fluorescent PCR reaction system is:
。
7. The application of the real-time fluorescence PCR reaction system in detecting cryptococcus neoformans and cryptococcus gatherens is characterized in that the real-time fluorescence PCR reaction system comprises a primer, a probe 1 and a probe 2; the primer consists of SEQ ID NO: 1 and the sequence shown in SEQ ID NO: 2 is shown in the specification; the probe 1 is as follows: FAM 5'-TCGGATGATGATCCTCAGACCGACC-3' BHQ1, wherein the probe 2 is: HEX 5'-TCGGATGATGATCCTGAGACCGACG-3' BHQ 1.
8. The use of claim 7, wherein the real-time fluorescent PCR reaction system is:
。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111405179.5A CN113862393A (en) | 2020-03-10 | 2020-11-11 | Method for rapidly detecting cryptococcus gatherensis |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010159845.0A CN111763756A (en) | 2020-03-10 | 2020-03-10 | Method for rapidly detecting cryptococcus gatherensis |
CN2020101598450 | 2020-03-10 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202111405179.5A Division CN113862393A (en) | 2020-03-10 | 2020-11-11 | Method for rapidly detecting cryptococcus gatherensis |
Publications (1)
Publication Number | Publication Date |
---|---|
CN112359125A true CN112359125A (en) | 2021-02-12 |
Family
ID=72719064
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010159845.0A Pending CN111763756A (en) | 2020-03-10 | 2020-03-10 | Method for rapidly detecting cryptococcus gatherensis |
CN202111405179.5A Pending CN113862393A (en) | 2020-03-10 | 2020-11-11 | Method for rapidly detecting cryptococcus gatherensis |
CN202011254539.1A Pending CN112359125A (en) | 2020-03-10 | 2020-11-11 | Method for rapidly detecting cryptococcus gatherensis |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010159845.0A Pending CN111763756A (en) | 2020-03-10 | 2020-03-10 | Method for rapidly detecting cryptococcus gatherensis |
CN202111405179.5A Pending CN113862393A (en) | 2020-03-10 | 2020-11-11 | Method for rapidly detecting cryptococcus gatherensis |
Country Status (1)
Country | Link |
---|---|
CN (3) | CN111763756A (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116334280A (en) * | 2023-02-17 | 2023-06-27 | 首都医科大学附属北京世纪坛医院 | Identification method, primer pair and kit for cryptococcus |
CN117106966A (en) * | 2023-10-11 | 2023-11-24 | 首都医科大学附属北京世纪坛医院 | Primer pair, method and kit for detecting cryptococcus garvieae |
CN117265162A (en) * | 2023-10-11 | 2023-12-22 | 首都医科大学附属北京世纪坛医院 | Primer probe combination, method and kit for detecting cryptococcus garvieae |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113881789B (en) * | 2021-09-30 | 2024-01-19 | 北京大学第一医院 | Probe and primer pair composition for detecting cryptococcus and detection method and application |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101880729A (en) * | 2010-08-06 | 2010-11-10 | 复旦大学附属华山医院 | Detection method and kit for microfluidic high-throughput of pathogenic fungi |
JP5835702B2 (en) * | 2011-03-03 | 2015-12-24 | 学校法人帝京大学 | Detection method and detection kit for cryptococcosis-causing bacteria |
CN106893782B (en) * | 2017-03-21 | 2019-08-27 | 中国人民解放军总医院 | It is a kind of to detect and identify cryptococcal target gene, primer and probe and kit |
CN108060263B (en) * | 2018-02-10 | 2020-03-06 | 杭州缔蓝生物技术有限公司 | Primer probe combination and fluorescent quantitative PCR kit for simultaneously detecting three cryptococci |
CN110863037A (en) * | 2019-11-15 | 2020-03-06 | 北京贝尔生物工程股份有限公司 | Microarray chip capable of detecting various fungal genome DNAs (deoxyribonucleic acids) and preparation method thereof |
-
2020
- 2020-03-10 CN CN202010159845.0A patent/CN111763756A/en active Pending
- 2020-11-11 CN CN202111405179.5A patent/CN113862393A/en active Pending
- 2020-11-11 CN CN202011254539.1A patent/CN112359125A/en active Pending
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116334280A (en) * | 2023-02-17 | 2023-06-27 | 首都医科大学附属北京世纪坛医院 | Identification method, primer pair and kit for cryptococcus |
CN117106966A (en) * | 2023-10-11 | 2023-11-24 | 首都医科大学附属北京世纪坛医院 | Primer pair, method and kit for detecting cryptococcus garvieae |
CN117265162A (en) * | 2023-10-11 | 2023-12-22 | 首都医科大学附属北京世纪坛医院 | Primer probe combination, method and kit for detecting cryptococcus garvieae |
Also Published As
Publication number | Publication date |
---|---|
CN113862393A (en) | 2021-12-31 |
CN111763756A (en) | 2020-10-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN112359125A (en) | Method for rapidly detecting cryptococcus gatherensis | |
CN110760620A (en) | Classical swine fever virus and African classical swine fever virus dual-fluorescence PCR detection reagent, kit and detection method | |
CN111004862B (en) | Primer and probe for rapidly detecting and identifying cryptococcus and application thereof | |
CN112359126A (en) | Method for accurately detecting cryptococcus neoformans | |
CN109913565B (en) | Kit, primer pair, probe and method for detecting vibrio parahaemolyticus | |
CN103898108A (en) | Nucleotide specific to Vibrio fluvialis O2, O4, O13, O15 and O18 and application thereof | |
CN110735006A (en) | African swine fever TaqMan real-time fluorescent quantitative PCR (polymerase chain reaction) detection primer and kit | |
CN111471797B (en) | RT-RPA primer pair, probe, kit and detection method for detecting cat coronavirus | |
CN108707691A (en) | A kind of primer combination of probe of specific detection aspergillus fumigatus and the kit that aspergillus fumigatus is detected based on fluorescent PCR method | |
CN112011650B (en) | Chinese bee sacbrood virus RT-RPA detection primer, probe and kit | |
CN109735645B (en) | Real-time fluorescent PCR (polymerase chain reaction) primer, probe and kit for detecting Sporothrix globosum | |
CN103993090A (en) | Specific nucleotides for providencia O31, O41, O42, O43 and O50 and application of specific nucleotides | |
CN116814859A (en) | Primer probe composition, kit and method for identifying African swine fever virus genes I and II | |
CN106916903A (en) | The real-time fluorescence RT PCR detection methods and kit of mycobacterium tuberculosis 85B mRNA | |
CN110564882A (en) | Dual TaqMAN probe fluorescent quantitative PCR detection method for equine piroplasmosis | |
CN116121439A (en) | Method and kit for detecting fungi by multiple quantitative PCR | |
CN107164506B (en) | Method for detecting multiple sheep babesia and detection kit | |
CN113106167B (en) | Primer and probe for invasive aspergillosis pathogenic bacteria, implementation method and detection system thereof | |
CN115029460A (en) | Instant visual detection method for haemophilus parasuis | |
CN115181803A (en) | Taqman probe qPCR detection primer group for detecting chaulmoogra and application | |
CN113718053A (en) | Probe and primer pair for detecting yersinia sporogenes, detection method and application | |
CN107557456B (en) | LAMP (loop-mediated isothermal amplification) detection primer group and kit for ureaplasma urealyticum | |
CN109207623B (en) | Fluorescent PCR (polymerase chain reaction) primer, probe and detection kit for identifying three sporothrix bacteria | |
CN114381458B (en) | Ortsutsugamushi quantitative detection kit based on droplet PCR | |
CN114350846B (en) | Primer group and kit for combined detection of multiple pulmonary infection fungi |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
TA01 | Transfer of patent application right | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20211124 Address after: Room 02, 5 / F, 101, building 2, zone 3, No. 186, South Fourth Ring West Road, Fengtai District, Beijing 100070 Applicant after: Beijing liangjue Technology Co.,Ltd. Address before: 100038, Beijing, Haidian District, Fang Fang shop, No. 10, iron road Applicant before: BEIJING SHIJITAN HOSPITAL, CMU |
|
WD01 | Invention patent application deemed withdrawn after publication | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20210212 |